Cargando…
97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/ http://dx.doi.org/10.1016/j.annonc.2021.03.111 |
| _version_ | 1783689749648637952 |
|---|---|
| author | Angelis, V. McFarlane, P. Cunningham, N. Gennatas, S. Johnston, S.R.D. Okines, A. McGrath, S. |
| author_facet | Angelis, V. McFarlane, P. Cunningham, N. Gennatas, S. Johnston, S.R.D. Okines, A. McGrath, S. |
| author_sort | Angelis, V. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8106264 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81062642021-05-10 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience Angelis, V. McFarlane, P. Cunningham, N. Gennatas, S. Johnston, S.R.D. Okines, A. McGrath, S. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-05 2021-05-08 /pmc/articles/PMC8106264/ http://dx.doi.org/10.1016/j.annonc.2021.03.111 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Angelis, V. McFarlane, P. Cunningham, N. Gennatas, S. Johnston, S.R.D. Okines, A. McGrath, S. 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
| title | 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
| title_full | 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
| title_fullStr | 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
| title_full_unstemmed | 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
| title_short | 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
| title_sort | 97p is continuing cdk4-6 inhibitor therapy safe during the covid-19 pandemic? a uk cancer centre experience |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/ http://dx.doi.org/10.1016/j.annonc.2021.03.111 |
| work_keys_str_mv | AT angelisv 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience AT mcfarlanep 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience AT cunninghamn 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience AT gennatass 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience AT johnstonsrd 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience AT okinesa 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience AT mcgraths 97piscontinuingcdk46inhibitortherapysafeduringthecovid19pandemicaukcancercentreexperience |